T Cells Derived from Umbilical Cord Blood
AssigneeAbraham J and Phyllis Katz Cord Blood Foundation
InventorsMary Laughlin, Jeong Su Do
Life of this patent
Estimating the term…
Abstract
Methods for producing therapeutic T cells from umbilical cord blood are provided. Methods for treating immune-related diseases or conditions (e.g. autoimmune diseases, transplant rejection, cancer) using umbilical cord blood derived therapeutic T cells are also provided. Compositions comprising umbilical cord blood derived therapeutic T cells are also provided.
Claims28
A method for producing inducible regulatory T cells (iTregs) from blood comprising:
- providing blood;
- isolating naïve CD4+ T cells from the blood;
- inducing the naïve CD4+ T cells to differentiate into a first composition comprising iTregs;
- separating the iTregs from the first composition to form a substantially purified iTreg composition;
- and
- expanding the purified iTreg composition over a mesenchymal stromal cell (MSC) feeder layer to form an expanded iTreg composition.
An inducible regulatory T cell composition comprising the expanded iTreg composition produced by any of the above claims.
A method for treating an inflammatory or an autoimmune condition in a human subject in need thereof comprising:
- administering to the subject a composition comprising a therapeutically effective dose of umbilical cord blood derived iTregs expanded over mesenchymal stromal cells.
A therapeutic regulatory T cell composition comprising a therapeutically effective dose of umbilical cord blood derived iTregs expanded over mesenchymal stromal cells.
A method for producing therapeutic T cells from umbilical cord blood comprising:
- providing umbilical cord blood;
- isolating naïve CD4+ T cells from the umbilical cord blood;
- and
- differentiating the naïve CD4+ T cells into iTregs by inducing BACH2 transcriptional regulation of FOXP3 expression.
A method for treating an immune-related disease or condition in a subject in need thereof comprising:
- administering to the subject a composition comprising a therapeutically effective dose of an umbilical cord blood derived therapeutic T cell composition, wherein the umbilical cord blood derived therapeutic T cell composition or a precursor thereto has been previously differentiated by inducing BACH2 transcriptional regulation of FOXP3 expression and has been cultured over a mesenchymal stromal cell feeder layer.
A therapeutic composition comprising a therapeutically effective dose of an umbilical cord blood derived therapeutic T cell composition, wherein the umbilical cord blood derived therapeutic T cell composition or a precursor thereto has been previously differentiated by inducing BACH2 transcriptional regulation of FOXP3 expression and cultured over a mesenchymal stromal cell feeder layer.
Dependencies are inferred from the claim text.